LAG3 and melanoma: While studies evaluating LAG-3 therapies rarely profile NK cells, one study evaluating the response of patients with melanoma to a combination of anti-LAG-3 and anti-PD-1 found that adaptive LAG-3+ NK cells were most prominent in those who responded to immunotherapy (348).